Investing Experience -
Risk Profile -
Followers
0
Following
0
Blog Posts
0
Threads
2,267
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
2,267
Past 30 days
0
Past 7 days
0
Today
0
User Comments
Stock
2020-09-08 17:46 | Report Abuse
https://www.theedgemarkets.com/article/heitech-padu-confirms-bidding-niis-says-collaborations-are-way-forward
Citing sources, the report said My EG Services Bhd (MyEG) was bidding for the contract with HeiTech Padu and S5 Systems Sdn Bhd as a consortium.
Stock
2020-09-08 17:44 | Report Abuse
https://www.theedgemarkets.com/article/heitech-padu-confirms-bidding-niis-says-collaborations-are-way-forward
Citing sources, the report said My EG Services Bhd (MyEG) was bidding for the contract with HeiTech Padu and S5 Systems Sdn Bhd as a consortium.
Stock
2020-09-04 20:03 | Report Abuse
（莫斯科4日讯）俄罗斯工业和贸易部长曼图罗夫指，该国第一款新冠肺炎疫苗，计划下月起大规模生产，并于明年开始每月生产数百万剂。
综合媒体报导，俄罗斯正研发多款疫苗，其中由莫斯科“加马列亚”流行病与微生物学研究所研发的一款疫苗，目前处于后期研发阶段，且已向当局申请注册。
曼图罗夫于当地时间周一称：“我们预计于9月开始量产，每月可生产数十万剂，最终在明年初起增至每月数百万剂”。这款疫苗属“病毒载体疫苗”，是利用其他病毒携带脱氧核糖核酸（DNA），借此引发细胞的免疫反应。
据报，上述疫苗测试是由俄罗斯直接投资基金（RDIF）所资助，其首席执行员德米特里耶夫表示，预计疫苗可于10天内完成注册，“若然成事，我们将是全球首款注册的新冠肺炎疫苗，早于美国及其他国家”。
而另一款由位于西伯利亚的国家病毒学和生物技术研究中心研发的疫苗，正进行临床测试，另有两款疫苗将于未来两个月内进行人体测试。
Stock
2020-09-04 20:01 | Report Abuse
（莫斯科4日讯）俄罗斯工业和贸易部长曼图罗夫指，该国第一款新冠肺炎疫苗，计划下月起大规模生产，并于明年开始每月生产数百万剂。
综合媒体报导，俄罗斯正研发多款疫苗，其中由莫斯科“加马列亚”流行病与微生物学研究所研发的一款疫苗，目前处于后期研发阶段，且已向当局申请注册。
曼图罗夫于当地时间周一称：“我们预计于9月开始量产，每月可生产数十万剂，最终在明年初起增至每月数百万剂”。这款疫苗属“病毒载体疫苗”，是利用其他病毒携带脱氧核糖核酸（DNA），借此引发细胞的免疫反应。
据报，上述疫苗测试是由俄罗斯直接投资基金（RDIF）所资助，其首席执行员德米特里耶夫表示，预计疫苗可于10天内完成注册，“若然成事，我们将是全球首款注册的新冠肺炎疫苗，早于美国及其他国家”。
而另一款由位于西伯利亚的国家病毒学和生物技术研究中心研发的疫苗，正进行临床测试，另有两款疫苗将于未来两个月内进行人体测试。
Stock
2020-09-04 20:01 | Report Abuse
（莫斯科4日讯）俄罗斯工业和贸易部长曼图罗夫指，该国第一款新冠肺炎疫苗，计划下月起大规模生产，并于明年开始每月生产数百万剂。
综合媒体报导，俄罗斯正研发多款疫苗，其中由莫斯科“加马列亚”流行病与微生物学研究所研发的一款疫苗，目前处于后期研发阶段，且已向当局申请注册。
曼图罗夫于当地时间周一称：“我们预计于9月开始量产，每月可生产数十万剂，最终在明年初起增至每月数百万剂”。这款疫苗属“病毒载体疫苗”，是利用其他病毒携带脱氧核糖核酸（DNA），借此引发细胞的免疫反应。
据报，上述疫苗测试是由俄罗斯直接投资基金（RDIF）所资助，其首席执行员德米特里耶夫表示，预计疫苗可于10天内完成注册，“若然成事，我们将是全球首款注册的新冠肺炎疫苗，早于美国及其他国家”。
而另一款由位于西伯利亚的国家病毒学和生物技术研究中心研发的疫苗，正进行临床测试，另有两款疫苗将于未来两个月内进行人体测试。
Stock
2020-09-04 20:00 | Report Abuse
（莫斯科4日讯）俄罗斯工业和贸易部长曼图罗夫指，该国第一款新冠肺炎疫苗，计划下月起大规模生产，并于明年开始每月生产数百万剂。
综合媒体报导，俄罗斯正研发多款疫苗，其中由莫斯科“加马列亚”流行病与微生物学研究所研发的一款疫苗，目前处于后期研发阶段，且已向当局申请注册。
曼图罗夫于当地时间周一称：“我们预计于9月开始量产，每月可生产数十万剂，最终在明年初起增至每月数百万剂”。这款疫苗属“病毒载体疫苗”，是利用其他病毒携带脱氧核糖核酸（DNA），借此引发细胞的免疫反应。
据报，上述疫苗测试是由俄罗斯直接投资基金（RDIF）所资助，其首席执行员德米特里耶夫表示，预计疫苗可于10天内完成注册，“若然成事，我们将是全球首款注册的新冠肺炎疫苗，早于美国及其他国家”。
而另一款由位于西伯利亚的国家病毒学和生物技术研究中心研发的疫苗，正进行临床测试，另有两款疫苗将于未来两个月内进行人体测试。
Stock
2020-09-04 19:59 | Report Abuse
（莫斯科4日讯）俄罗斯工业和贸易部长曼图罗夫指，该国第一款新冠肺炎疫苗，计划下月起大规模生产，并于明年开始每月生产数百万剂。
综合媒体报导，俄罗斯正研发多款疫苗，其中由莫斯科“加马列亚”流行病与微生物学研究所研发的一款疫苗，目前处于后期研发阶段，且已向当局申请注册。
曼图罗夫于当地时间周一称：“我们预计于9月开始量产，每月可生产数十万剂，最终在明年初起增至每月数百万剂”。这款疫苗属“病毒载体疫苗”，是利用其他病毒携带脱氧核糖核酸（DNA），借此引发细胞的免疫反应。
据报，上述疫苗测试是由俄罗斯直接投资基金（RDIF）所资助，其首席执行员德米特里耶夫表示，预计疫苗可于10天内完成注册，“若然成事，我们将是全球首款注册的新冠肺炎疫苗，早于美国及其他国家”。
而另一款由位于西伯利亚的国家病毒学和生物技术研究中心研发的疫苗，正进行临床测试，另有两款疫苗将于未来两个月内进行人体测试。
Stock
Stock
2020-09-04 19:57 | Report Abuse
（莫斯科4日讯）俄罗斯工业和贸易部长曼图罗夫指，该国第一款新冠肺炎疫苗，计划下月起大规模生产，并于明年开始每月生产数百万剂。
综合媒体报导，俄罗斯正研发多款疫苗，其中由莫斯科“加马列亚”流行病与微生物学研究所研发的一款疫苗，目前处于后期研发阶段，且已向当局申请注册。
曼图罗夫于当地时间周一称：“我们预计于9月开始量产，每月可生产数十万剂，最终在明年初起增至每月数百万剂”。这款疫苗属“病毒载体疫苗”，是利用其他病毒携带脱氧核糖核酸（DNA），借此引发细胞的免疫反应。
据报，上述疫苗测试是由俄罗斯直接投资基金（RDIF）所资助，其首席执行员德米特里耶夫表示，预计疫苗可于10天内完成注册，“若然成事，我们将是全球首款注册的新冠肺炎疫苗，早于美国及其他国家”。
而另一款由位于西伯利亚的国家病毒学和生物技术研究中心研发的疫苗，正进行临床测试，另有两款疫苗将于未来两个月内进行人体测试。
Stock
Stock
2020-09-04 19:56 | Report Abuse
（莫斯科4日讯）俄罗斯工业和贸易部长曼图罗夫指，该国第一款新冠肺炎疫苗，计划下月起大规模生产，并于明年开始每月生产数百万剂。
综合媒体报导，俄罗斯正研发多款疫苗，其中由莫斯科“加马列亚”流行病与微生物学研究所研发的一款疫苗，目前处于后期研发阶段，且已向当局申请注册。
曼图罗夫于当地时间周一称：“我们预计于9月开始量产，每月可生产数十万剂，最终在明年初起增至每月数百万剂”。这款疫苗属“病毒载体疫苗”，是利用其他病毒携带脱氧核糖核酸（DNA），借此引发细胞的免疫反应。
据报，上述疫苗测试是由俄罗斯直接投资基金（RDIF）所资助，其首席执行员德米特里耶夫表示，预计疫苗可于10天内完成注册，“若然成事，我们将是全球首款注册的新冠肺炎疫苗，早于美国及其他国家”。
而另一款由位于西伯利亚的国家病毒学和生物技术研究中心研发的疫苗，正进行临床测试，另有两款疫苗将于未来两个月内进行人体测试。
Stock
Stock
2020-09-04 16:43 | Report Abuse
Dancomech正极催化剂
1）新收购将在未来1-3年内贡献3-5百万
2）红利> 3％++
3）以便宜的价格进行交易X PE12应该以XPE 18-20进行交易
4）管理层希望公司成长-预计未来3年的复合年增长率为20％（收入增长三倍，从8000万令吉增至2.4亿我）这将很容易在未来3年将其盈利能力提高至2500万令吉以上
5）继续寻找并购
6）净现金公司6400万令吉
7）经济衰退证明
超过30年
8）成功占领海外市场的更多份额-
9.非常成功地收购mtl，其pe的现金机会成本仅为pe的6倍，因此增值率仅为2％。
10.交叉销售danco n mtl业务将增强集团实力。
除了涉及空调部件的MTL之外，大约两年前danco还收购了为Danco做出贡献的泵业制造。
11. Danco还收购了物料处理业务，这证明了在成功实现其核心阀门业务稳步有机增长的同时，通过并购扩大并购实力。
12. danco集团的新结构将分为四个部分。
即：
1.核心阀n备件业务
2.泵制造业务。
3.物料搬运工程业务。
4.暖通空调，工具和模具的制造业务。
13，大股东持股72％++
前30％持有85.7％的市场流通量，而仅持有15％的市场。 公司可能会采取奖金形式的公司活动，以根据其有利可图的扩张来提高其市场流动性。
14.目前，danco是阀门业务的市场领导者，其毛利率平均为40％，颇具吸引力。
多年来，公司不仅为自己的品牌建立市场，还为校长分配了知名品牌。
目前，自有品牌占阀门销售量的50％。
15.技术图表势头强劲，其股价已开始突破更高的水平。
FY20 X PE 15 = TP 0.75
FY20 X PE 18 = TP 0.90
Stock
2020-09-04 16:42 | Report Abuse
Dancomech Positive Catalyst
1) New Acquisition will contribute 3-5mil in next 1-3 yrs
2) Good Dividend > 3%++
3) Trade @ Cheap valuation X PE12 should Trade @ XPE 18-20
4)Management desire to growth the company -Expected CAGR 20% in Next 3yrs (revenue growth Triple from rm80mil to me 240mil) This will easily raise its profitabilty to above rm 25m in next 3yrs
5)Continue look for M&A
6) Nett Cash Company rm64mil
7)Recession proof business model
Over pass 30yrs
8)Successfully capture more market share for overseas market -
9. Very successful acquisition of mtl with pe 6x earnings accretive bearing in opportunity cost of its cash is only 2% pa.
10. There is cross selling of danco n mtl business that will enhance the group.
Beside mtl which is involve with air conditioning components, automotive and furniture components manufacturing about 2 year earlier danco had acquired a pump manufacturing that had contributed to danco.
11. Danco also had acquired a material handling business this prove the m&a prowess of expanding thru acquisition beside successful steady organic growth its core valve business.
12. The new structure of danco group will have 4 segment .
Namely:
1.core valve n spare parts business
2. Pump manufacturing business.
3. Material handling engineering business.
4. Manufacturing business of hvac, tools and dies.
13.Major shareholders Hold 72%++
Top 30% hold 85.7% market float ard 15% only. It likely there will be corporate exercise in the form of bonus to raise its market liquidity in line with its profitably expansion.
14.Currently danco is the market leader in the valve business and its gross profit margin is quite attractive at average 40%.
The company distributor reputable brands for principals beside market its own brand build up over the years.
Currently its own brand comprises 50% of the valve sell.
15. Technical chart n momentum appear its share price has start breaking out to a higher level moving forward.
FY20 X PE 15 = TP 0.75
FY20 X PE 18 = TP 0.90
Stock
Stock
Stock
2020-09-02 18:46 | Report Abuse
(Kuala Lumpur, 2nd) Due to the strong turnover of foreign labor-related services, brokerages expect that the stock price of MYEG Services (MYEG, 0138, the main board technology) has the potential to rise by another 25% in the next few months. Explore a 5-year high of RM2.90.
MYEG's share price closed at 1.46 ringgit on Tuesday (1st), which is 92% higher than the 76.5 sen trough that fell during the movement control order.
At the close of the market, the stock rose from 1 sen to RM1.47, with approximately 30.75 million shares traded.
In order to effectively manage the border, the government hopes to fully implement the National Centralized Immigration System (NIISE) at all checkpoints across the country in 2023 to replace the existing immigration system. CGS-CIMB Securities pointed out that if the MYEG service can obtain the relevant contract, the stock price may even rise to 2.90 ringgit.
However, in addition to the support of the centralized immigration system across the country, the company's business has also made some positive progress recently, because the government has agreed to provide accommodation on the issue of freezing foreign workers, allowing employers to re-employ foreign workers who are unemployed but hold work permits. , Allowing MYEG services to restore the main source of income.
MYEG Service also pointed out that the increase in the share of online service transactions between the Road Transport Bureau and immigration-related services will also help offset the impact of the decrease in foreign labor recruitment.
On the other hand, the foreign labor pneumonia screening platform that the company cooperated with the Ministry of Labor has so far carried out about 100,000 tests, and the test target for the year is 500,000.
"I believe this will further increase the potential of the screening platform
Stock
Stock
Stock
Stock
2020-09-02 18:44 | Report Abuse
(Kuala Lumpur, 2nd) Due to the strong turnover of foreign labor-related services, brokerages expect that the stock price of MYEG Services (MYEG, 0138, the main board technology) has the potential to rise by another 25% in the next few months. Explore a 5-year high of RM2.90.
MYEG's share price closed at 1.46 ringgit on Tuesday (1st), which is 92% higher than the 76.5 sen trough that fell during the movement control order.
At the close of the market, the stock rose from 1 sen to RM1.47, with approximately 30.75 million shares traded.
In order to effectively manage the border, the government hopes to fully implement the National Centralized Immigration System (NIISE) at all checkpoints across the country in 2023 to replace the existing immigration system. CGS-CIMB Securities pointed out that if the MYEG service can obtain the relevant contract, the stock price may even rise to 2.90 ringgit.
However, in addition to the support of the centralized immigration system across the country, the company's business has also made some positive progress recently, because the government has agreed to provide accommodation on the issue of freezing foreign workers, allowing employers to re-employ foreign workers who are unemployed but hold work permits. , Allowing MYEG services to restore the main source of income.
MYEG Service also pointed out that the increase in the share of online service transactions between the Road Transport Bureau and immigration-related services will also help offset the impact of the decrease in foreign labor recruitment.
On the other hand, the foreign labor pneumonia screening platform that the company cooperated with the Ministry of Labor has so far carried out about 100,000 tests, and the test target for the year is 500,000.
"I believe this will further increase the potential of the screening platform
Stock
2020-09-02 18:43 | Report Abuse
(Kuala Lumpur, 2nd) Due to the strong turnover of foreign labor-related services, brokerages expect that the stock price of MYEG Services (MYEG, 0138, the main board technology) has the potential to rise by another 25% in the next few months. Explore a 5-year high of RM2.90.
MYEG's share price closed at 1.46 ringgit on Tuesday (1st), which is 92% higher than the 76.5 sen trough that fell during the movement control order.
At the close of the market, the stock rose from 1 sen to RM1.47, with approximately 30.75 million shares traded.
In order to effectively manage the border, the government hopes to fully implement the National Centralized Immigration System (NIISE) at all checkpoints across the country in 2023 to replace the existing immigration system. CGS-CIMB Securities pointed out that if the MYEG service can obtain the relevant contract, the stock price may even rise to 2.90 ringgit.
However, in addition to the support of the centralized immigration system across the country, the company's business has also made some positive progress recently, because the government has agreed to provide accommodation on the issue of freezing foreign workers, allowing employers to re-employ foreign workers who are unemployed but hold work permits. , Allowing MYEG services to restore the main source of income.
MYEG Service also pointed out that the increase in the share of online service transactions between the Road Transport Bureau and immigration-related services will also help offset the impact of the decrease in foreign labor recruitment.
On the other hand, the foreign labor pneumonia screening platform that the company cooperated with the Ministry of Labor has so far carried out about 100,000 tests, and the test target for the year is 500,000.
"I believe this will further increase the potential of the screening platform
Stock
Stock
Stock
2020-09-02 14:18 | Report Abuse
高达50%的节省优惠哪里找？ NAK BELI by MYEG让你越买越省！
https://www.chinapress.com.my/?p=2175120
Stock
2020-09-02 14:16 | Report Abuse
高达50%的节省优惠哪里找？ NAK BELI by MYEG让你越买越省！
https://www.chinapress.com.my/?p=2175120
Stock
Stock
2020-09-02 12:40 | Report Abuse
Highlight - Analysts see MyEG as hidden gem poised to soar - http://www.theedgemarkets.com/article/analysts-see-myeg-hidden-gem-poised-soar (Share from StockHunter)
Stock
2020-09-02 12:39 | Report Abuse
Highlight - Analysts see MyEG as hidden gem poised to soar - http://www.theedgemarkets.com/article/analysts-see-myeg-hidden-gem-poised-soar (Share from StockHunter)
Stock
2020-09-02 12:38 | Report Abuse
Highlight - Analysts see MyEG as hidden gem poised to soar - http://www.theedgemarkets.com/article/analysts-see-myeg-hidden-gem-poised-soar (Share from StockHunter)
Stock
2020-09-02 12:37 | Report Abuse
Highlight - Analysts see MyEG as hidden gem poised to soar - http://www.theedgemarkets.com/article/analysts-see-myeg-hidden-gem-poised-soar (Share from StockHunter)
Stock
2020-09-02 09:40 | Report Abuse
Will break > 040... next QR should very good. company is growing demand for semiconductors, particularly through its manufacturing division’s automatic vision inspection and automated handling equipments.
Stock
2020-09-02 09:36 | Report Abuse
CASH FLOW STRONG.
MEDICAL DIVICE INDUSTRY WILL CONTINUE TO EXHIBIT GOOD GROWTH.
MARGIN INCREASE BECAUSE OF DEVICES BIZ.
ZERO BORROWING.
STRONG & RELIABLE MANAGEMENT.
FAMILY OF HSUEH HOLDED 67.67%.
TWO BIG LISTED CAMPANIES SCOMNET'S 大客户 , EDWARDS LIFE SCIENCE AND AMBU.
刚刚签下不久的另一个大客户，MERMAID MEDICAL，再大大刺激订单，FY2020-FY2021 ！
（独家分销商！）
转至主板可能性非常高！
现金高达RM50 mil ！
零负债！没贷款！
赚副预计从15%至18%！
预料2026年里，心血管设备市场规模会达USD 822 亿！！！
全球由5个主要商参与，其中一个就是SCOMNET的大客户！
FY2020 净利料RM28mil， FY2021 净利RM35 mil！
ON TRACK TO DELIVER RECORD EARNINGS WITH ACCELERATED GROWTH IN EPS OF 59% IN FY2020 & 41% IN fy2021.
STRONG GROWTH CAGR 30%!
Stock
Stock
Stock
2020-08-31 16:28 | Report Abuse
Coronavirus outbreak
Alarm as FDA willing to issue Covid-19 vaccine before stringent safety testing
FDA under intensifying pressure from Trump, who wants to see a vaccine come on stream or ready to announce before the election
Ed Pilkington in New York
@edpilkington
Sun 30 Aug 2020 21.12 BST
Public health experts have reacted with alarm to remarks by the head of the US Food and Drug Administration (FDA) that he might give the green light for a US Covid-19 vaccine before the normal clinical trial process had reached its conclusion.
As the US was on the verge of 6m coronavirus cases on Sunday, Stephen Hahn, the FDA commissioner, told the Financial Times in an interview published on Sunday that he was prepared to issue emergency use authorization for a Covid-19 vaccine before the end of Phase 3 human trials that put the drug through stringent testing for safety and efficacy.
He said the standard he would apply instead would be “that the benefit outweighs the risk in a public health emergency”.
Hahn told the newspaper that his decision would not be swayed by political pressure amid the febrile atmosphere of the upcoming US presidential election. “This is going to be a science, medicine, data decision. This is not going to be a political decision,” he said.
But several public health experts expressed their concern on Sunday about an apparent willingness to consider fast-tracking a vaccine outside what is considered the gold standard testing process.
The FDA has come under intensifying pressure in recent weeks from Donald Trump, who wants to see a vaccine come on stream or ready to announce before the November election, and has a public-private vaccine development funding program underway called Operation Warp Speed.
Trump has openly attacked the FDA, baselessly citing a supposed “deep state” within it of dragging its feet on the vaccine approval process, despite no evidence to support the latest version of a right-wing conspiracy theory that even one of its most enthusiastic, original Trump administration propagators, Steve Bannon, has dismissed.
The number of confirmed cases of Covid-19 was approaching 6m in the US by Sunday afternoon, according to figures from Johns Hopkins University, while recorded deaths stand at a catastrophic 182,612 – almost a quarter of all global fatalities.
Over the weekend California became the first state to pass 700,000 confirmed cases.
Since the beginning of the pandemic in January, Trump has consistently downplayed the severity of the crisis and sidelined scientists, including those at the FDA.
Hahn has been criticized for misleading the public about the efficacy of convalescent plasma treatment which takes blood plasma from Covid-19 survivors and injects it into sufferers.
At a White House media launch last week Hahn, standing beside Trump, said the plasma treatment would save 35 lives out of every 100 patients when in fact studies put the figure at 3 to 5 lives. He was forced to apologise.
Scientists and public health specialists were quick to issue warnings about Hahn’s comments about cutting short the vaccine trials.
Dr Angela Rasmussen, a virologist at New York’s Columbia University, said: “We absolutely cannot tolerate or accept an emergency authorization for any Covid-19 vaccine without reliable safety and efficacy data from phase three clinical trials”.
Stock
2020-08-31 16:22 | Report Abuse
Coronavirus outbreak
Alarm as FDA willing to issue Covid-19 vaccine before stringent safety testing
FDA under intensifying pressure from Trump, who wants to see a vaccine come on stream or ready to announce before the election
Ed Pilkington in New York
@edpilkington
Sun 30 Aug 2020 21.12 BST
Public health experts have reacted with alarm to remarks by the head of the US Food and Drug Administration (FDA) that he might give the green light for a US Covid-19 vaccine before the normal clinical trial process had reached its conclusion.
As the US was on the verge of 6m coronavirus cases on Sunday, Stephen Hahn, the FDA commissioner, told the Financial Times in an interview published on Sunday that he was prepared to issue emergency use authorization for a Covid-19 vaccine before the end of Phase 3 human trials that put the drug through stringent testing for safety and efficacy.
He said the standard he would apply instead would be “that the benefit outweighs the risk in a public health emergency”.
Hahn told the newspaper that his decision would not be swayed by political pressure amid the febrile atmosphere of the upcoming US presidential election. “This is going to be a science, medicine, data decision. This is not going to be a political decision,” he said.
But several public health experts expressed their concern on Sunday about an apparent willingness to consider fast-tracking a vaccine outside what is considered the gold standard testing process.
The FDA has come under intensifying pressure in recent weeks from Donald Trump, who wants to see a vaccine come on stream or ready to announce before the November election, and has a public-private vaccine development funding program underway called Operation Warp Speed.
Trump has openly attacked the FDA, baselessly citing a supposed “deep state” within it of dragging its feet on the vaccine approval process, despite no evidence to support the latest version of a right-wing conspiracy theory that even one of its most enthusiastic, original Trump administration propagators, Steve Bannon, has dismissed.
The number of confirmed cases of Covid-19 was approaching 6m in the US by Sunday afternoon, according to figures from Johns Hopkins University, while recorded deaths stand at a catastrophic 182,612 – almost a quarter of all global fatalities.
Over the weekend California became the first state to pass 700,000 confirmed cases.
Since the beginning of the pandemic in January, Trump has consistently downplayed the severity of the crisis and sidelined scientists, including those at the FDA.
Hahn has been criticized for misleading the public about the efficacy of convalescent plasma treatment which takes blood plasma from Covid-19 survivors and injects it into sufferers.
At a White House media launch last week Hahn, standing beside Trump, said the plasma treatment would save 35 lives out of every 100 patients when in fact studies put the figure at 3 to 5 lives. He was forced to apologise.
Scientists and public health specialists were quick to issue warnings about Hahn’s comments about cutting short the vaccine trials.
Dr Angela Rasmussen, a virologist at New York’s Columbia University, said: “We absolutely cannot tolerate or accept an emergency authorization for any Covid-19 vaccine without reliable safety and efficacy data from phase three clinical trials”.
Writing on Twitter, she said it would be unethical to give the go-ahead before the trials had conclusively proved that both the safety and efficacy of the vaccine.
It would place “huge numbers of people at risk for massive potential harm” and would deal “a catastrophic blow to public confidence in both vaccines and the regulatory mechanisms in place”, she wrote.
Eric Topol of the Scripps Translational Research Institute said that it would take many months for the safety of the vaccine to be fully determined at trial, “irrespective of Stephen Hahn’s subservience to Trump… Any shortcuts will imperil the ultimate rollout of the vaccine and lose the public trust for getting immunized, which is already compromised.”
Hahn’s predecessor as head of the FDA, Scott Gottlieb, told CBS’s Face the Nation that “I don’t know what is meant by saying before the phase 3 trials are completed… They are going to wait for these trials to read out before they can make a decision about the efficacy of these vaccines.”
The news earlier this month that Russia had produced a vaccine was greeted with widespread skepticism because it had been approved and was being given to people, including one of Vladimir Putin’s daughters, before phase three trials
Stock
2020-08-31 16:22 | Report Abuse
Coronavirus outbreak
Alarm as FDA willing to issue Covid-19 vaccine before stringent safety testing
FDA under intensifying pressure from Trump, who wants to see a vaccine come on stream or ready to announce before the election
Ed Pilkington in New York
@edpilkington
Sun 30 Aug 2020 21.12 BST
Public health experts have reacted with alarm to remarks by the head of the US Food and Drug Administration (FDA) that he might give the green light for a US Covid-19 vaccine before the normal clinical trial process had reached its conclusion.
As the US was on the verge of 6m coronavirus cases on Sunday, Stephen Hahn, the FDA commissioner, told the Financial Times in an interview published on Sunday that he was prepared to issue emergency use authorization for a Covid-19 vaccine before the end of Phase 3 human trials that put the drug through stringent testing for safety and efficacy.
He said the standard he would apply instead would be “that the benefit outweighs the risk in a public health emergency”.
Hahn told the newspaper that his decision would not be swayed by political pressure amid the febrile atmosphere of the upcoming US presidential election. “This is going to be a science, medicine, data decision. This is not going to be a political decision,” he said.
But several public health experts expressed their concern on Sunday about an apparent willingness to consider fast-tracking a vaccine outside what is considered the gold standard testing process.
The FDA has come under intensifying pressure in recent weeks from Donald Trump, who wants to see a vaccine come on stream or ready to announce before the November election, and has a public-private vaccine development funding program underway called Operation Warp Speed.
Trump has openly attacked the FDA, baselessly citing a supposed “deep state” within it of dragging its feet on the vaccine approval process, despite no evidence to support the latest version of a right-wing conspiracy theory that even one of its most enthusiastic, original Trump administration propagators, Steve Bannon, has dismissed.
The number of confirmed cases of Covid-19 was approaching 6m in the US by Sunday afternoon, according to figures from Johns Hopkins University, while recorded deaths stand at a catastrophic 182,612 – almost a quarter of all global fatalities.
Over the weekend California became the first state to pass 700,000 confirmed cases.
Since the beginning of the pandemic in January, Trump has consistently downplayed the severity of the crisis and sidelined scientists, including those at the FDA.
Hahn has been criticized for misleading the public about the efficacy of convalescent plasma treatment which takes blood plasma from Covid-19 survivors and injects it into sufferers.
At a White House media launch last week Hahn, standing beside Trump, said the plasma treatment would save 35 lives out of every 100 patients when in fact studies put the figure at 3 to 5 lives. He was forced to apologise.
Scientists and public health specialists were quick to issue warnings about Hahn’s comments about cutting short the vaccine trials.
Dr Angela Rasmussen, a virologist at New York’s Columbia University, said: “We absolutely cannot tolerate or accept an emergency authorization for any Covid-19 vaccine without reliable safety and efficacy data from phase three clinical trials”.
Writing on Twitter, she said it would be unethical to give the go-ahead before the trials had conclusively proved that both the safety and efficacy of the vaccine.
It would place “huge numbers of people at risk for massive potential harm” and would deal “a catastrophic blow to public confidence in both vaccines and the regulatory mechanisms in place”, she wrote.
Eric Topol of the Scripps Translational Research Institute said that it would take many months for the safety of the vaccine to be fully determined at trial, “irrespective of Stephen Hahn’s subservience to Trump… Any shortcuts will imperil the ultimate rollout of the vaccine and lose the public trust for getting immunized, which is already compromised.”
Hahn’s predecessor as head of the FDA, Scott Gottlieb, told CBS’s Face the Nation that “I don’t know what is meant by saying before the phase 3 trials are completed… They are going to wait for these trials to read out before they can make a decision about the efficacy of these vaccines.”
The news earlier this month that Russia had produced a vaccine was greeted with widespread skepticism because it had been approved and was being given to people, including one of Vladimir Putin’s daughters, before phase three trials
Stock
2020-08-31 16:21 | Report Abuse
Coronavirus outbreak
Alarm as FDA willing to issue Covid-19 vaccine before stringent safety testing
FDA under intensifying pressure from Trump, who wants to see a vaccine come on stream or ready to announce before the election
Ed Pilkington in New York
@edpilkington
Sun 30 Aug 2020 21.12 BST
Public health experts have reacted with alarm to remarks by the head of the US Food and Drug Administration (FDA) that he might give the green light for a US Covid-19 vaccine before the normal clinical trial process had reached its conclusion.
As the US was on the verge of 6m coronavirus cases on Sunday, Stephen Hahn, the FDA commissioner, told the Financial Times in an interview published on Sunday that he was prepared to issue emergency use authorization for a Covid-19 vaccine before the end of Phase 3 human trials that put the drug through stringent testing for safety and efficacy.
He said the standard he would apply instead would be “that the benefit outweighs the risk in a public health emergency”.
Hahn told the newspaper that his decision would not be swayed by political pressure amid the febrile atmosphere of the upcoming US presidential election. “This is going to be a science, medicine, data decision. This is not going to be a political decision,” he said.
But several public health experts expressed their concern on Sunday about an apparent willingness to consider fast-tracking a vaccine outside what is considered the gold standard testing process.
The FDA has come under intensifying pressure in recent weeks from Donald Trump, who wants to see a vaccine come on stream or ready to announce before the November election, and has a public-private vaccine development funding program underway called Operation Warp Speed.
Trump has openly attacked the FDA, baselessly citing a supposed “deep state” within it of dragging its feet on the vaccine approval process, despite no evidence to support the latest version of a right-wing conspiracy theory that even one of its most enthusiastic, original Trump administration propagators, Steve Bannon, has dismissed.
The number of confirmed cases of Covid-19 was approaching 6m in the US by Sunday afternoon, according to figures from Johns Hopkins University, while recorded deaths stand at a catastrophic 182,612 – almost a quarter of all global fatalities.
Over the weekend California became the first state to pass 700,000 confirmed cases.
Since the beginning of the pandemic in January, Trump has consistently downplayed the severity of the crisis and sidelined scientists, including those at the FDA.
Hahn has been criticized for misleading the public about the efficacy of convalescent plasma treatment which takes blood plasma from Covid-19 survivors and injects it into sufferers.
At a White House media launch last week Hahn, standing beside Trump, said the plasma treatment would save 35 lives out of every 100 patients when in fact studies put the figure at 3 to 5 lives. He was forced to apologise.
Scientists and public health specialists were quick to issue warnings about Hahn’s comments about cutting short the vaccine trials.
Dr Angela Rasmussen, a virologist at New York’s Columbia University, said: “We absolutely cannot tolerate or accept an emergency authorization for any Covid-19 vaccine without reliable safety and efficacy data from phase three clinical trials”.
Writing on Twitter, she said it would be unethical to give the go-ahead before the trials had conclusively proved that both the safety and efficacy of the vaccine.
It would place “huge numbers of people at risk for massive potential harm” and would deal “a catastrophic blow to public confidence in both vaccines and the regulatory mechanisms in place”, she wrote.
Eric Topol of the Scripps Translational Research Institute said that it would take many months for the safety of the vaccine to be fully determined at trial, “irrespective of Stephen Hahn’s subservience to Trump… Any shortcuts will imperil the ultimate rollout of the vaccine and lose the public trust for getting immunized, which is already compromised.”
Hahn’s predecessor as head of the FDA, Scott Gottlieb, told CBS’s Face the Nation that “I don’t know what is meant by saying before the phase 3 trials are completed… They are going to wait for these trials to read out before they can make a decision about the efficacy of these vaccines.”
The news earlier this month that Russia had produced a vaccine was greeted with widespread skepticism because it had been approved and was being given to people, including one of Vladimir Putin’s daughters, before phase three trials
Stock
2020-08-31 16:20 | Report Abuse
Coronavirus outbreak
Alarm as FDA willing to issue Covid-19 vaccine before stringent safety testing
FDA under intensifying pressure from Trump, who wants to see a vaccine come on stream or ready to announce before the election
Ed Pilkington in New York
@edpilkington
Sun 30 Aug 2020 21.12 BST
Public health experts have reacted with alarm to remarks by the head of the US Food and Drug Administration (FDA) that he might give the green light for a US Covid-19 vaccine before the normal clinical trial process had reached its conclusion.
As the US was on the verge of 6m coronavirus cases on Sunday, Stephen Hahn, the FDA commissioner, told the Financial Times in an interview published on Sunday that he was prepared to issue emergency use authorization for a Covid-19 vaccine before the end of Phase 3 human trials that put the drug through stringent testing for safety and efficacy.
He said the standard he would apply instead would be “that the benefit outweighs the risk in a public health emergency”.
Hahn told the newspaper that his decision would not be swayed by political pressure amid the febrile atmosphere of the upcoming US presidential election. “This is going to be a science, medicine, data decision. This is not going to be a political decision,” he said.
But several public health experts expressed their concern on Sunday about an apparent willingness to consider fast-tracking a vaccine outside what is considered the gold standard testing process.
The FDA has come under intensifying pressure in recent weeks from Donald Trump, who wants to see a vaccine come on stream or ready to announce before the November election, and has a public-private vaccine development funding program underway called Operation Warp Speed.
Trump has openly attacked the FDA, baselessly citing a supposed “deep state” within it of dragging its feet on the vaccine approval process, despite no evidence to support the latest version of a right-wing conspiracy theory that even one of its most enthusiastic, original Trump administration propagators, Steve Bannon, has dismissed.
The number of confirmed cases of Covid-19 was approaching 6m in the US by Sunday afternoon, according to figures from Johns Hopkins University, while recorded deaths stand at a catastrophic 182,612 – almost a quarter of all global fatalities.
Over the weekend California became the first state to pass 700,000 confirmed cases.
Since the beginning of the pandemic in January, Trump has consistently downplayed the severity of the crisis and sidelined scientists, including those at the FDA.
Hahn has been criticized for misleading the public about the efficacy of convalescent plasma treatment which takes blood plasma from Covid-19 survivors and injects it into sufferers.
At a White House media launch last week Hahn, standing beside Trump, said the plasma treatment would save 35 lives out of every 100 patients when in fact studies put the figure at 3 to 5 lives. He was forced to apologise.
Scientists and public health specialists were quick to issue warnings about Hahn’s comments about cutting short the vaccine trials.
Dr Angela Rasmussen, a virologist at New York’s Columbia University, said: “We absolutely cannot tolerate or accept an emergency authorization for any Covid-19 vaccine without reliable safety and efficacy data from phase three clinical trials”.
Writing on Twitter, she said it would be unethical to give the go-ahead before the trials had conclusively proved that both the safety and efficacy of the vaccine.
It would place “huge numbers of people at risk for massive potential harm” and would deal “a catastrophic blow to public confidence in both vaccines and the regulatory mechanisms in place”, she wrote.
Eric Topol of the Scripps Translational Research Institute said that it would take many months for the safety of the vaccine to be fully determined at trial, “irrespective of Stephen Hahn’s subservience to Trump… Any shortcuts will imperil the ultimate rollout of the vaccine and lose the public trust for getting immunized, which is already compromised.”
Hahn’s predecessor as head of the FDA, Scott Gottlieb, told CBS’s Face the Nation that “I don’t know what is meant by saying before the phase 3 trials are completed… They are going to wait for these trials to read out before they can make a decision about the efficacy of these vaccines.”
The news earlier this month that Russia had produced a vaccine was greeted with widespread skepticism because it had been approved and was being given to people, including one of Vladimir Putin’s daughters, before phase three trials
Stock
2020-08-31 16:19 | Report Abuse
Coronavirus outbreak
Alarm as FDA willing to issue Covid-19 vaccine before stringent safety testing
FDA under intensifying pressure from Trump, who wants to see a vaccine come on stream or ready to announce before the election
Ed Pilkington in New York
@edpilkington
Sun 30 Aug 2020 21.12 BST
Public health experts have reacted with alarm to remarks by the head of the US Food and Drug Administration (FDA) that he might give the green light for a US Covid-19 vaccine before the normal clinical trial process had reached its conclusion.
As the US was on the verge of 6m coronavirus cases on Sunday, Stephen Hahn, the FDA commissioner, told the Financial Times in an interview published on Sunday that he was prepared to issue emergency use authorization for a Covid-19 vaccine before the end of Phase 3 human trials that put the drug through stringent testing for safety and efficacy.
He said the standard he would apply instead would be “that the benefit outweighs the risk in a public health emergency”.
Hahn told the newspaper that his decision would not be swayed by political pressure amid the febrile atmosphere of the upcoming US presidential election. “This is going to be a science, medicine, data decision. This is not going to be a political decision,” he said.
But several public health experts expressed their concern on Sunday about an apparent willingness to consider fast-tracking a vaccine outside what is considered the gold standard testing process.
The FDA has come under intensifying pressure in recent weeks from Donald Trump, who wants to see a vaccine come on stream or ready to announce before the November election, and has a public-private vaccine development funding program underway called Operation Warp Speed.
Trump has openly attacked the FDA, baselessly citing a supposed “deep state” within it of dragging its feet on the vaccine approval process, despite no evidence to support the latest version of a right-wing conspiracy theory that even one of its most enthusiastic, original Trump administration propagators, Steve Bannon, has dismissed.
The number of confirmed cases of Covid-19 was approaching 6m in the US by Sunday afternoon, according to figures from Johns Hopkins University, while recorded deaths stand at a catastrophic 182,612 – almost a quarter of all global fatalities.
Over the weekend California became the first state to pass 700,000 confirmed cases.
Since the beginning of the pandemic in January, Trump has consistently downplayed the severity of the crisis and sidelined scientists, including those at the FDA.
Hahn has been criticized for misleading the public about the efficacy of convalescent plasma treatment which takes blood plasma from Covid-19 survivors and injects it into sufferers.
At a White House media launch last week Hahn, standing beside Trump, said the plasma treatment would save 35 lives out of every 100 patients when in fact studies put the figure at 3 to 5 lives. He was forced to apologise.
Scientists and public health specialists were quick to issue warnings about Hahn’s comments about cutting short the vaccine trials.
Dr Angela Rasmussen, a virologist at New York’s Columbia University, said: “We absolutely cannot tolerate or accept an emergency authorization for any Covid-19 vaccine without reliable safety and efficacy data from phase three clinical trials”.
Writing on Twitter, she said it would be unethical to give the go-ahead before the trials had conclusively proved that both the safety and efficacy of the vaccine.
It would place “huge numbers of people at risk for massive potential harm” and would deal “a catastrophic blow to public confidence in both vaccines and the regulatory mechanisms in place”, she wrote.
Eric Topol of the Scripps Translational Research Institute said that it would take many months for the safety of the vaccine to be fully determined at trial, “irrespective of Stephen Hahn’s subservience to Trump… Any shortcuts will imperil the ultimate rollout of the vaccine and lose the public trust for getting immunized, which is already compromised.”
Hahn’s predecessor as head of the FDA, Scott Gottlieb, told CBS’s Face the Nation that “I don’t know what is meant by saying before the phase 3 trials are completed… They are going to wait for these trials to read out before they can make a decision about the efficacy of these vaccines.”
The news earlier this month that Russia had produced a vaccine was greeted with widespread skepticism because it had been approved and was being given to people, including one of Vladimir Putin’s daughters, before phase three trials
Stock
2020-08-31 16:19 | Report Abuse
Coronavirus outbreak
Alarm as FDA willing to issue Covid-19 vaccine before stringent safety testing
FDA under intensifying pressure from Trump, who wants to see a vaccine come on stream or ready to announce before the election
Ed Pilkington in New York
@edpilkington
Sun 30 Aug 2020 21.12 BST
Public health experts have reacted with alarm to remarks by the head of the US Food and Drug Administration (FDA) that he might give the green light for a US Covid-19 vaccine before the normal clinical trial process had reached its conclusion.
As the US was on the verge of 6m coronavirus cases on Sunday, Stephen Hahn, the FDA commissioner, told the Financial Times in an interview published on Sunday that he was prepared to issue emergency use authorization for a Covid-19 vaccine before the end of Phase 3 human trials that put the drug through stringent testing for safety and efficacy.
He said the standard he would apply instead would be “that the benefit outweighs the risk in a public health emergency”.
Hahn told the newspaper that his decision would not be swayed by political pressure amid the febrile atmosphere of the upcoming US presidential election. “This is going to be a science, medicine, data decision. This is not going to be a political decision,” he said.
But several public health experts expressed their concern on Sunday about an apparent willingness to consider fast-tracking a vaccine outside what is considered the gold standard testing process.
The FDA has come under intensifying pressure in recent weeks from Donald Trump, who wants to see a vaccine come on stream or ready to announce before the November election, and has a public-private vaccine development funding program underway called Operation Warp Speed.
Trump has openly attacked the FDA, baselessly citing a supposed “deep state” within it of dragging its feet on the vaccine approval process, despite no evidence to support the latest version of a right-wing conspiracy theory that even one of its most enthusiastic, original Trump administration propagators, Steve Bannon, has dismissed.
The number of confirmed cases of Covid-19 was approaching 6m in the US by Sunday afternoon, according to figures from Johns Hopkins University, while recorded deaths stand at a catastrophic 182,612 – almost a quarter of all global fatalities.
Over the weekend California became the first state to pass 700,000 confirmed cases.
Since the beginning of the pandemic in January, Trump has consistently downplayed the severity of the crisis and sidelined scientists, including those at the FDA.
Hahn has been criticized for misleading the public about the efficacy of convalescent plasma treatment which takes blood plasma from Covid-19 survivors and injects it into sufferers.
At a White House media launch last week Hahn, standing beside Trump, said the plasma treatment would save 35 lives out of every 100 patients when in fact studies put the figure at 3 to 5 lives. He was forced to apologise.
Scientists and public health specialists were quick to issue warnings about Hahn’s comments about cutting short the vaccine trials.
Dr Angela Rasmussen, a virologist at New York’s Columbia University, said: “We absolutely cannot tolerate or accept an emergency authorization for any Covid-19 vaccine without reliable safety and efficacy data from phase three clinical trials”.
Writing on Twitter, she said it would be unethical to give the go-ahead before the trials had conclusively proved that both the safety and efficacy of the vaccine.
It would place “huge numbers of people at risk for massive potential harm” and would deal “a catastrophic blow to public confidence in both vaccines and the regulatory mechanisms in place”, she wrote.
Eric Topol of the Scripps Translational Research Institute said that it would take many months for the safety of the vaccine to be fully determined at trial, “irrespective of Stephen Hahn’s subservience to Trump… Any shortcuts will imperil the ultimate rollout of the vaccine and lose the public trust for getting immunized, which is already compromised.”
Hahn’s predecessor as head of the FDA, Scott Gottlieb, told CBS’s Face the Nation that “I don’t know what is meant by saying before the phase 3 trials are completed… They are going to wait for these trials to read out before they can make a decision about the efficacy of these vaccines.”
The news earlier this month that Russia had produced a vaccine was greeted with widespread skepticism because it had been approved and was being given to people, including one of Vladimir Putin’s daughters, before phase three trials
Stock
Stock
Stock
Stock
2020-08-31 14:09 | Report Abuse
next QR should very good. company is growing demand for semiconductors, particularly through its manufacturing division’s automatic vision inspection and automated handling equipments.
Stock
2020-08-31 14:05 | Report Abuse
christophertopher scomne 生產t 特殊業務 -醫療設備電纜
Stock
Stock
2020-08-30 11:59 | Report Abuse
At the end still come back DPHARMA and Pharmaniaga for vaccines
Stock: [DSONIC]: DATASONIC GROUP BERHAD
2020-09-08 17:53 | Report Abuse
10 things I learned from the 2020 MYEG Services AGM and EGM - https://fifthperson.com/2020-myeg-services-agm-egm/ (Share from StockHunter)